Gilead Sciences Inc. (GILD)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
80.64-0.73 (-0.90%)
As of 12:53 PM EDT. Market open.
People also watch:
CELGBIIBAMGNREGNBMY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open81.00
Prev Close81.37
Bid80.57 x 500
Ask80.58 x 300
Day's Range79.92 - 81.13
52wk Range76.67 - 111.11
1y Target EstN/A
Market Cap106.42B
P/E Ratio (ttm)7.08
Beta1.00
Volume4,414,996
Avg Vol (3m)10,652,700
Dividend & Yield1.88 (2.31%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • TheStreet.com46 minutes ago

    Stocks Lower as Wall Street Turns Attention to Clinton-Trump Debate

    Stocks hold lower by midday Monday as Wall Street's attention shifts to the looming presidential debate from central bank policy.

  • Market Realist2 hours ago

    What’s the Upside Potential for Gilead?

    According to a Bloomberg consensus of 28 brokerage firms on September 20, 2016, 60.7% of the firms rated Gilead a “buy,” while 39.3% rated it a “hold.”

  • Barrons.com2 hours ago

    Gilead Sciences: A 'Slight Uplift' for R&D Strategy?

    Over the weekend, Gilead Sciences (GILD) partner Galapagos (GLPG) announced positive results from a Phase II trial for a Crohn's disease treatment. Leerink's Geoffrey Porges and Bradley Canino consider the implications: Last night, Gilead partner Galapagos announced endoscopic and histopathological results, for FITZROY, their phase 2 trial of JAK1 inhibitor filgotinib in Crohn's disease – with positive trends observed for the treatment arms. With regard to endoscopic data, the percentage of actively treated patients with a Simple Endoscopic Score for Crohn's Disease (SES-CD) improvement of at least 50% was 25% in contrast to the percentage of patients receiving placebo, which was 13.6%.